title: The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels.
abstract: Proinflammatory cytokines may be important in the pathogenesis of human immunodeficiency virus type 1 (HIV-1) disease. Tenidap decreases interleukin (IL)-6, IL-1, and tumor necrosis factor (TNF) production by peripheral blood mononuclear cells and decreases IL-6 plasma levels in rheumatoid arthritis patients. In this randomized double-blind study, 43 HIV-1-infected patients received tenidap (120 mg) or placebo daily for 6 weeks and then crossed over to the alternative therapy for an additional 6 weeks. Mean entry CD4 cell count was 140/microL. Analyses were performed on cytokines, acute-phase proteins, virus load, and CD4 cell counts. With the exception of small differences in plasma TNF levels, tenidap had no significant effect on these indices. Significant correlations of plasma IL-6 and TNF levels with HIV-1 RNA were noted. Six patients discontinued tenidap due to rash. The effects of tenidap in HIV-1 infection contrast to results in arthritis patients, in whom tenidap decreased plasma levels of IL-6 and acute-phase proteins.
authors.affiliation: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
authors.forename: B J
authors.initials: BJ
authors.lastname: Dezube
authors.forename: M M
authors.initials: MM
authors.lastname: Lederman
authors.forename: B
authors.initials: B
authors.lastname: Chapman
authors.forename: D L
authors.initials: DL
authors.lastname: Georges
authors.forename: A L
authors.initials: AL
authors.lastname: Dogon
authors.forename: P
authors.initials: P
authors.lastname: Mudido
authors.forename: J
authors.initials: J
authors.lastname: Reis-Lishing
authors.forename: S L
authors.initials: SL
authors.lastname: Cheng
authors.forename: S L
authors.initials: SL
authors.lastname: Silberman
authors.forename: C S
authors.initials: CS
authors.lastname: Crumpacker
mesh_terms: D000209:Acute-Phase Proteins / Q000032:analysis*; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D018791:CD4 Lymphocyte Count; D018592:Cross-Over Studies; D016207:Cytokines / Q000097:blood*; D004311:Double-Blind Method; D016655:HIV Core Protein p24 / Q000097:blood; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D000078183:Oxindoles; D012367:RNA, Viral / Q000097:blood; D000685:Serum Amyloid A Protein / Q000032:analysis; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D019562:Viral Load
chemical_list: D000209:Acute-Phase Proteins; D019380:Anti-HIV Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D016655:HIV Core Protein p24; D007211:Indoles; D007375:Interleukin-1; D015850:Interleukin-6; D000078183:Oxindoles; D012367:RNA, Viral; D000685:Serum Amyloid A Protein; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; C062866:tenidap